Expression of CD24 in adenocarcinomas of the pancreas correlates with higher tumor grades

Pancreatology. 2004;4(5):454-60. doi: 10.1159/000079824. Epub 2004 Jul 14.


Background/aims: CD24 is expressed in hematological malignancies as well as in a large variety of solid tumors and is often associated with a more aggressive course of the disease. We aimed to evaluate CD24 protein expression in pancreatic adenocarcinomas and to correlate it to clinicopathological data including patient survival.

Methods: 95 primary adenocarcinomas of the pancreas were immunostained using a monoclonal CD24 antibody (Ab-2, clone 24C02). Staining was evaluated as negative versus positive for statistical analysis.

Results: CD24 expression was observed in 71.6% of cases with a heterogeneous distribution, and a significantly higher rate of positivity in high grade (G3) tumors. In univariate survival analyses, no association of CD24 expression with shortened overall survival of the patients could be demonstrated.

Conclusion: CD24 is commonly expressed in adenocarcinomas of the pancreas, preferentially high-grade tumors and thus might be a marker of disease progression.

MeSH terms

  • Adenocarcinoma / metabolism*
  • Adenocarcinoma / pathology*
  • Adult
  • Aged
  • Aged, 80 and over
  • Antigens, CD / metabolism*
  • Biomarkers, Tumor / metabolism
  • CD24 Antigen
  • Female
  • Humans
  • Immunohistochemistry / methods
  • Male
  • Membrane Glycoproteins / metabolism*
  • Middle Aged
  • Pancreas / metabolism
  • Pancreatic Neoplasms / metabolism*
  • Pancreatic Neoplasms / pathology*
  • Prognosis
  • Staining and Labeling
  • Survival Analysis


  • Antigens, CD
  • Biomarkers, Tumor
  • CD24 Antigen
  • CD24 protein, human
  • Membrane Glycoproteins